RAF阻害剤は,野生型BRAFを有する細胞におけるRAFダイマーとERKシグナル伝達をトランザクティベーションする
Poulikos I Poulikakos1, Chao Zhang, Gideon Bollag
1Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Nature
|February 25, 2010
まとめ
RAF阻害剤は,パラドックスな活性化を防ぐことで,BRAF変異性腫瘍におけるERKシグナル伝達を阻害する. このメカニズムは,それらの有効性を説明し,MEK阻害剤と比較してより良い治療指標を予測します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 薬理学 薬理学とは
背景:
- BRAF変異を持つ腫瘍は,RAF-MEK-ERK経路に依存して成長する.
- RAF阻害剤は,変異したBRAF細胞とは異なり,野生型のBRAF細胞におけるERKシグナリングを逆説的に強化する.
研究 の 目的:
- 野生型BRAF細胞におけるRAF阻害体によるパラドックスなERK信号活性化のメカニズム的基礎を解明する.
- 変異型対野生型BRAFの文脈におけるRAF阻害剤の差異的効果を理解する.
主な方法:
- RAFのダイマートランザクティベーションを調査するために,化学遺伝的方法を使用しました.
- ERKシグナル誘導の薬物結合とRAS活性への依存性を分析した.
主要な成果:
- RAFダイマーの薬物媒介によるトランザクティベーションは,RAF阻害剤によるパラドックスなERK活性化を引き起こします.
- ERKシグナリング誘導には,ATP結合部位とRAS活性に直接薬物結合が必要です.
- BRAF (V600E) 腫瘍では,最小限のRAS活性化により,RAF阻害剤によるERKシグナル伝達が阻害される.
結論:
- RAF阻害剤は,最小限のパラドックスな活性化により,BRAF変異の腫瘍に有効です.
- RAF阻害剤は,MEK阻害剤よりも高い治療指数とより高い抗腫瘍活性を提供することがあります.
- RAF発現またはRAS活性が増加すると,BRAF変異性腫瘍の薬剤耐性を促進する可能性があります.
関連する概念動画
The Ras Gene
5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
5.7K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Interactions Between Signaling Pathways
4.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Receptor Tyrosine Kinases
15.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
MAPK Signaling Cascades
7.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K


